Citadel Advisors
SNDX icon

Citadel Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Citadel Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.65M Sell
258,278
-372,664
-59% -$7.75M ﹤0.01% 4511
2026
Q1 		$14.7M Buy
630,942
+446,939
+243% +$9.71M ﹤0.01% 2707
2025
Q4 		$3.87M Sell
184,003
-362,265
-66% -$6.32M ﹤0.01% 4724
2025
Q3 		$8.4M Sell
546,268
-93,732
-15% -$1.23M ﹤0.01% 3518
2025
Q2 		$5.99M Sell
640,000
-2,274,882
-78% -$25M ﹤0.01% 3807
2025
Q1 		$35.8M Buy
2,914,882
+1,825,079
+167% +$25.7M 0.01% 1438
2024
Q4 		$14.4M Buy
1,089,803
+1,055,783
+3,103% +$18.1M ﹤0.01% 2541
2024
Q3 		$655K Sell
34,020
-155,961
-82% -$3.22M ﹤0.01% 7691
2024
Q2 		$3.9M Buy
189,981
+156,172
+462% +$3.27M ﹤0.01% 4146
2024
Q1 		$805K Sell
33,809
-209,176
-86% -$4.67M ﹤0.01% 7380
2023
Q4 		$5.25M Sell
242,985
-192,508
-44% -$2.96M ﹤0.01% 3709
2023
Q3 		$6.32M Buy
435,493
+198,543
+84% +$3.76M ﹤0.01% 3300
2023
Q2 		$4.96M Sell
236,950
-1,342,719
-85% -$28M ﹤0.01% 3670
2023
Q1 		$33.4M Sell
1,579,669
-48,184
-3% -$1.2M 0.01% 1437
2022
Q4 		$41.4M Buy
1,627,853
+261,082
+19% +$6.09M 0.01% 1274
2022
Q3 		$32.8M Sell
1,366,771
-362,281
-21% -$8.13M 0.01% 1393
2022
Q2 		$33.3M Sell
1,729,052
-96,388
-5% -$1.61M 0.01% 1392
2022
Q1 		$31.7M Sell
1,825,440
-193,387
-10% -$3.26M 0.01% 1490
2021
Q4 		$44.2M Buy
2,018,827
+175,470
+10% +$3.24M 0.01% 1268
2021
Q3 		$35.2M Sell
1,843,357
-115,274
-6% -$1.92M 0.01% 1423
2021
Q2 		$33.6M Sell
1,958,631
-271,492
-12% -$4.97M 0.01% 1496
2021
Q1 		$49.9M Buy
2,230,123
+118,605
+6% +$2.68M 0.01% 1044
2020
Q4 		$47M Buy
2,111,518
+1,549,104
+275% +$32.1M 0.01% 991
2020
Q3 		$8.3M Sell
562,414
-479,166
-46% -$7.3M ﹤0.01% 2511
2020
Q2 		$15.4M Buy
1,041,580
+1,028,435
+7,824% +$15.7M 0.01% 1744
2020
Q1 		$144K Sell
13,145
-9,053
-41% -$85K ﹤0.01% 8337
2019
Q4 		$195K Buy
+22,198
New +$163K ﹤0.01% 8213
2019
Q1 		– Sell
-35,007
Closed -$200K – 9828
2018
Q4 		$156K Sell
35,007
-23,048
-40% -$126K ﹤0.01% 8034
2018
Q3 		$469K Buy
58,055
+35,557
+158% +$253K ﹤0.01% 6804
2018
Q2 		$158K Buy
+22,498
New +$221K ﹤0.01% 8036

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Citadel Advisors's SNDX Position: Q2 2026 in Review

Citadel Advisors reduced its Syndax Pharmaceuticals (SNDX) stake by 59% in Q2 2026, selling an estimated $7.75M and leaving 258,278 shares worth $5.65M. The position accounts for ﹤0.01% of the portfolio, ranked #4511.

Citadel Advisors first reported a position in SNDX in Q2 2018 and has held it in 30 quarters since. The position peaked at $49.9M in Q1 2021. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Citadel Advisors held 258,278 shares of Syndax Pharmaceuticals worth $5.65M as of Q2 2026.
  • Citadel Advisors sold 372,664 Syndax Pharmaceuticals shares in Q2 2026, an estimated $7.75M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4511 holding.
  • Citadel Advisors first reported a position in Syndax Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
  • Citadel Advisors's Syndax Pharmaceuticals position peaked at $49.9M in Q1 2021.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.